Compare STRT & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STRT | TECX |
|---|---|---|
| Founded | 1908 | 2019 |
| Country | United States | United States |
| Employees | N/A | 51 |
| Industry | Auto Parts:O.E.M. | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 378.2M | 393.0M |
| IPO Year | 1996 | N/A |
| Metric | STRT | TECX |
|---|---|---|
| Price | $80.40 | $35.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $80.40 |
| AVG Volume (30 Days) | 34.6K | ★ 523.8K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.53 | N/A |
| EPS | ★ 3.26 | N/A |
| Revenue | ★ $439,195,000.00 | N/A |
| Revenue This Year | $4.22 | N/A |
| Revenue Next Year | $2.04 | N/A |
| P/E Ratio | $25.22 | ★ N/A |
| Revenue Growth | ★ 5.24 | N/A |
| 52 Week Low | $31.71 | $13.70 |
| 52 Week High | $92.50 | $28.98 |
| Indicator | STRT | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 37.34 | 82.47 |
| Support Level | $77.01 | $16.83 |
| Resistance Level | $82.98 | N/A |
| Average True Range (ATR) | 3.02 | 2.37 |
| MACD | -1.32 | 1.06 |
| Stochastic Oscillator | 2.73 | 97.81 |
Strattec Security Corp designs develops, manufactures, and markets mechanical locks, electronically enhanced locks, and keys. It also produces ignition lock housings; and access control products, including latches, power sliding door systems, and door handles. Strattec ships products to customer locations in the United States, Canada, Mexico, Europe, South America, Korea, and China, and provides full-service aftermarket support. Strattec also supplies products for the heavy truck and recreational vehicle markets, as well as precision, die castings.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.